Clinical trials: Liver Neoplasms
Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma.
- Trial name
- NCT01754987
- Testing
- Ascorbic Acid + Sorafenib, Sorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Jefferson University
Hepatocellular Carcinoma
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
This research study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see the following: how effective this combination of study drugs will be in treating HCC how long subjects respond to these study drugs what…
- Trial name
- NCT01032850
- Testing
- Sorafenib & Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Carcinoma, Hepatocellular
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
The objective of this study was to evaluate efficacy and safety of regorafenib in patients with advanced liver cancer who had progressed after sorafenib treatment.
- Trial name
- RESORCE (NCT01774344)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 147 sites in United States, Argentina and 19 more
- Volunteers
- 573 people
- Sponsor
- Bayer
Colon Cancer Liver Metastasis
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
The purpose of this study is to determine the safety and efficacy of Thermodox, a thermally sensitive liposomal doxorubicin, in combination with thermal ablation in the treatment of hepatic colorectal liver metastases (CRLM).
- Trial name
- ABLATE (NCT01464593)
- Testing
- Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution, ThermoDox
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Imunon
Breast Cancer, Hepatitis C
Association of Hepatitis C Virus With Breast Cancer
Hepatitis C viral infection is a major health problem in Egypt. The management of breast cancer patients is often complicated by the presence of associated HCV infection.
- Trial name
- NCT04090164
- Where
- Egypt
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Gastrointestinal Cancer
Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
The study goal is to compare surgeon-palliative care team co-management, versus surgeon alone management, of patients and family members preparing for major upper gastrointestinal cancer surgery.
- Trial name
- PERIOP-PC (NCT03611309)
- Testing
- Surgeon-palliative care team co management, Surgeon team alone management
- Where
- 5 sites in United States
- Volunteers
- 379 people
- Sponsor
- Stanford University
Liver Cirrhosis
A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
This study is open to healthy adults and adults with liver cirrhosis. The purpose of this study is to compare how different medicines are handled by the body in people with and without liver cirrhosis.
- Trial name
- NCT05741372
- Testing
- Rosuvastatin, Digoxin, Metformin hydrochlorid
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Liver Cancer
Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta
Hepatocellular carcinoma is multifactorial in etiology and complex in pathogenesis, the blend of risk factors differs in different parts of the world, and this may explain in part the diverse biologic characteristics of HCC in…
- Trial name
- NCT02461966
- Testing
- Aflatoxin
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sherief Abd-Elsalam
Solid Tumor, Triple-negative Breast Cancer
A Study of LY3435151 in Participants With Solid Tumors
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04099277
- Testing
- LY3435151, Pembrolizumab
- Where
- 2 sites in United States, Japan
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC). It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor associated antigens, potentially increasing…
- Trial name
- NCT05776875
- Testing
- Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with lenvatinib and placebo in combination with lenvatinib in the treatment of…
- Trial name
- NCT04194775
- Testing
- Nofazinlimab (CS1003)+Lenvatinib
- Where
- 74 sites in United States, China and 4 more
- Volunteers
- 534 people
- Sponsor
- CStone Pharmaceuticals
Renal Cell Cancer, Melanoma
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of…
- Conditions
- Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT05061537
- Testing
- PF-07263689, Sasanlimab
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Colorectal Cancer
A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
The multicenter, open-label, single-arm, non-randomized, two-stage Simon's design, phase II study (The CLMO-001 Trial) will evaluate the efficacy and safety of bevacizumab in combination with mFOLFOX-6 (Levofolinic acid…
- Trial name
- NCT01383707
- Testing
- 5-Fluorouracil (5-FU), Bevacizumab, Levofolinic acid
- Where
- 11 sites in Italy
- Volunteers
- 77 people
- Sponsor
- Hoffmann-La Roche
Uveal Melanoma, Liver Metastases
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Patients with uveal melanoma metastatic to the liver will be treated with embolization of the hepatic artery every 4 weeks. GM-CSF (granulocyte-macrophage colony simulating factor) or normal saline will be injected into one of…
- Trial name
- NCT00661622
- Testing
- GM-CSF, Embolization
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hepatocellular Carcinoma
Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
This is a single-arm, single-center, open-label trial of pembrolizumab (MK-3475) in subjects with advanced hepatocellular carcinoma as second-line treatment after failure of sorafenib.
- Trial name
- NCT03163992
- Testing
- Pembrolizumab
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or…
- Trial name
- NCT03867084
- Testing
- Pembrolizumab
- Where
- 249 sites in United States, Argentina and 29 more
- Volunteers
- 959 people
- Sponsor
- Merck Sharp & Dohme LLC
Uterine Cervical Neoplasms, Endometrial Neoplasms
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected…
- Conditions
- Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms
- Trial name
- NCT05007106
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib
- Where
- 73 sites in United States, Canada and 13 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The purpose of the study is Find out if patients receiving Sorafenib will live longer Find out if Sorafenib has any effect on patient reported outcomes Find out if Sorafenib prevents the growth or shrinks liver tumors and / or…
- Trial name
- NCT00492752
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 23 sites in China, South Korea and 1 more
- Volunteers
- 226 people
- Sponsor
- Bayer
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
This phase II trial is studying how well giving doxorubicin together with bortezomib works in treating patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00083226
- Testing
- doxorubicin, bortezomib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma
This is a non-randomized, prospective, pilot, Multicenter Study of Drug-eluting bead transarterial chemoembolization (DEB-TACE) using Doxorubicin-Loaded Embozene® Tandem™ Microspheres to treat hepatocellular carcinoma (HCC).
- Trial name
- MIRACLE I (NCT01798134)
- Testing
- TANDEM™
- Where
- 7 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Boston Scientific Corporation